同花顺财经

麦格理资本:给予中国生物制药(01177.HK)“增持”评级 目标价10.22港元

2018-12-07 19:01:17      同花顺财经      

  麦格理资本12月6日发布公告。We believe the manufacturing sector may go through another two to three months of overhang as the actual implementation of procurement may be different from expectation. There are still a lot of unanswered questions such as when the next round of centralized procurement will be and what companies and drugs will be involved. For SINO, we put our numbers under review. Positive catalysts will come from new launches from its strong pipeline. We prefer the safer haven among drug distributors, which should not be affected much by near-term policy risks.

以上资讯由同花顺AI写手完成,写作系统尚处于测试阶段,内容仅供参考。

21